Jeffrey N. Simmons - Mar 3, 2025 Form 4 Insider Report for Elanco Animal Health Inc (ELAN)

Role: PRESIDENT, CEO AND DIRECTOR, Director
Signature: /s/ Amy C. Seidel, as Attorney-in-Fact for Jeffrey N. Simmons
Stock symbol: ELAN
Transactions as of: Mar 3, 2025
Transactions value $: $0
Form type: 4
Date filed: 3/5/2025, 06:49 PM
Previous filing: Mar 4, 2025
Next filing: Mar 11, 2025
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ELAN	Common Stock	Award	$0	+265K	+17.26%	$0.00	1.8M	Mar 3, 2025	Direct	F1
holding	ELAN	Common Stock						145K	Mar 3, 2025	By Revocable Trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ELAN	Employee Stock Option (right to buy)	Award	$0	+557K		$0.00	557K	Mar 3, 2025	Common Stock	557K	$11.31	Direct	F2
transaction	ELAN	Deferred Stock Units (Match)	Award	$0	+14.9K		$0.00	14.9K	Mar 3, 2025	Common Stock	14.9K		Direct	F3, F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Grant of restricted stock units vesting as follows: one-third vesting on March 3, 2026, one-third vesting on March 3, 2027, and the remaining vesting on March 3, 2028.
F2	Grant of stock options vesting as follows: one-third vesting on March 3, 2026, one-third vesting on March 3, 2027, and the remaining vesting on March 3, 2028.
F3	Each deferred stock unit represents the right to receive one share of Company common stock or the cash equivalent.
F4	Deferred stock units vest December 31, 2026 and settle upon termination of employment or otherwise in accordance with the Executive Deferral and Stock Match Plan.